FRED HUTCHINSON CANCER RESEARCH CENTER NON PROFIT CORPORATION

Their core work

Fred Hutchinson Cancer Research Center is a leading US non-profit biomedical research institution based in Seattle, Washington, internationally recognized for cancer immunotherapy, stem cell transplantation, and infectious disease research — particularly HIV/AIDS. In the H2020 program, they contributed specialized expertise in two areas: statistical multi-omics analysis of patient samples (SOUND) and HIV vaccine immunology, including virological assessment platforms and clinical trial design (EHVA). Their role in European consortia is that of a high-value transatlantic partner bringing world-class laboratory science, clinical research infrastructure, and biostatistical depth that European teams seek out for rigorous vaccine evaluation work.

What they specialise in

How they've shifted over time

Their two H2020 projects reveal a trajectory from broad computational biology toward applied translational immunology. SOUND (2015) positioned them as contributors to multi-omics statistical analysis of patient samples — a data-heavy, disease-agnostic capability. EHVA (2016) then anchored them firmly in HIV-specific vaccine science, emphasizing immunological and virological platforms alongside clinical trial methodology. The shift suggests that data integration remains a constant thread, but it is increasingly deployed in service of vaccine development rather than as a standalone bioinformatics function.

FHCRC is moving toward becoming a specialist transatlantic partner for EU vaccine consortia, where their immunological platforms and clinical trial expertise add measurable value to European-led discovery programs.

How they like to work

FHCRC has never held the coordinator role in H2020 — they consistently join as a contributing participant, which is typical for major US institutions engaging with EU programs where coordination sits with European legal entities. Despite only two projects, they engaged with 56 unique partners across 17 countries, meaning they plugged into large, multi-node European consortia rather than niche bilateral arrangements. This signals they are sought-after specialist contributors, not generalist consortium fillers.

Despite just two projects, FHCRC built a network of 56 unique partners spanning 17 countries — a footprint consistent with participation in large platform-type consortia like EHVA, which involved dozens of European and international institutions. Their geographic spread is global, not European-centric, reflecting their standing as a transatlantic research partner.

What sets them apart

As a US-based institution in H2020, FHCRC is a rare transatlantic asset — they bring access to US patient cohorts, clinical infrastructure, and internationally benchmarked immunological assay platforms that European partners typically cannot replicate internally. Their combination of HIV vaccine expertise and multi-omics data capability is particularly valuable for consortia that need both wet-lab immunology and computational analysis under one institutional roof. For consortium builders in infectious disease or oncology, FHCRC adds credibility and transatlantic reach that strengthens grant applications and broadens research impact.

Highlights from their portfolio

• EHVA
  The longest-running and highest-value project (2016–2023, EUR 310,879 received), EHVA is a major EU-wide HIV vaccine discovery platform — FHCRC's participation signals recognition as a world-class immunology partner by European funders.
• SOUND
  Reveals a distinct computational biology dimension — statistical multi-omics analysis of patient samples — showing FHCRC's capabilities extend beyond wet-lab immunology into biomedical data science.